Longevity & AgingGLP-1 Drugs May Target Aging Itself Beyond Just Treating Obesity
GLP-1 receptor agonists — the class of drugs that includes semaglutide and tirzepatide — have exploded in popularity for weight loss and diabetes. But a new perspective published in Nature Aging poses a deeper question: do these drugs actually slow the biology of aging itself, qualifying them as gerotherapeutics? The author reviews mounting evidence that GLP-1 drugs reduce inflammation, improve metabolic function, and lower risk of cardiovascular disease, kidney disease, and possibly neurodegeneration — all hallmarks of biological aging. The piece grapples with whether these wide-ranging benefits reflect a true geroprotective mechanism or are downstream effects of weight loss. The distinction matters enormously for how these drugs are prescribed, studied, and potentially approved for aging-related indications.
